{"id":70286,"date":"2016-05-08T05:00:19","date_gmt":"2016-05-08T05:00:19","guid":{"rendered":"http:\/\/mostafa.openonline.co.uk\/?guid=8d66e9b97db00e3f2095a1f6216864e6"},"modified":"2016-05-08T05:00:19","modified_gmt":"2016-05-08T05:00:19","slug":"press-release-life-science-leaders-say-uk-is-better-off-in-a-reformed-eu","status":"publish","type":"post","link":"https:\/\/mostafa.openonline.co.uk\/?p=70286","title":{"rendered":"Press release: Life science leaders say UK is better off in a reformed EU"},"content":{"rendered":"<div class=\"govspeak\">\n<div class=\"call-to-action\">\n<ul>\n<li>life science leaders warn being out on our own would bring uncertainty and added complexity to the industry and patients<\/li>\n<li>new government research shows <abbr title=\"United Kingdom\">UK<\/abbr> life sciences sector pumps more than \u00a360 billion in to the <abbr title=\"United Kingdom\">UK<\/abbr> economy and supports over 220,000 jobs<\/li>\n<li>pharmaceutical exports to <abbr title=\"European Union\">EU<\/abbr> countries generated \u00a311 billion for <abbr title=\"United Kingdom\">UK<\/abbr> economy in 2015 alone<\/li>\n<\/ul>\n<\/div>\n<p>The <abbr title=\"United Kingdom\">UK<\/abbr>\u2019s leading life science companies have today (8 May 2016) warned that leaving the <abbr title=\"European Union\">EU<\/abbr> could add risk to the wealth and health of the nation by bringing uncertainty to the industry, adding barriers to investment in the <abbr title=\"United Kingdom\">UK<\/abbr> and threatening access to the latest medicines.<\/p>\n<p>In today\u2019s letter to The Observer, the chief executives of the Association of British Pharmaceutical Industries (<abbr title=\"Association of British Pharmaceutical Industries\">ABPI<\/abbr>), Glaxo SmithKline, AstraZeneca and the BioIndustry Association are amongst over 90 signatories who claim that the future success of the <abbr title=\"United Kingdom\">UK<\/abbr> life sciences sector is underpinned by being part of the <abbr title=\"European Union\">EU<\/abbr>\u2019s single market, and <abbr title=\"European Union\">EU<\/abbr> regulatory processes.<\/p>\n<p>If the <abbr title=\"United Kingdom\">UK<\/abbr> was to leave a reformed Europe, companies would have to apply for separate market authorisations to sell their products in both the <abbr title=\"United Kingdom\">UK<\/abbr> and Europe \u2013 which could delay access for the millions of NHS patients to the latest drugs and treatments.<\/p>\n<p>The industry warning comes on the same day government published new statistics revealing the life sciences sector in the <abbr title=\"United Kingdom\">UK<\/abbr> has grown to \u00a360.7 billion, with the <abbr title=\"United Kingdom\">UK<\/abbr>\u2019s <abbr title=\"European Union\">EU<\/abbr> membership shown to be key to the sector\u2019s expansion. <\/p>\n<p>Life Sciences Minister George Freeman MP said:<\/p>\n<blockquote>\n<p>This is a serious warning from the leaders of the <abbr title=\"United Kingdom\">UK<\/abbr>\u2019s \u00a360 billion life science sector, which highlights the choice in this referendum: our economic security and global influence as part of the <abbr title=\"European Union\">EU<\/abbr>, or a leap in the dark.<\/p>\n<p class=\"last-child\">Being out on our own would risk the employment of 220,000 people, billions of pounds of inward investment, and our life science exports to the <abbr title=\"European Union\">EU<\/abbr> &#8211; which last year were worth over \u00a329 million every day.<\/p>\n<\/blockquote>\n<p>Mike Thompson, Chief Executive Officer, <abbr title=\"Association of British Pharmaceutical Industries\">ABPI<\/abbr>, said:<\/p>\n<blockquote>\n<p class=\"last-child\">Our members are overwhelmingly supportive of remaining in the <abbr title=\"European Union\">EU<\/abbr>. We believe that staying in the <abbr title=\"European Union\">EU<\/abbr> will mean that patients in the <abbr title=\"United Kingdom\">UK<\/abbr> will be more likely to get faster access to new medicines than if we left. It will also encourage global pharmaceutical companies to continue to invest, employ, research, manufacture and export in the <abbr title=\"United Kingdom\">UK<\/abbr>, rather than elsewhere.<\/p>\n<\/blockquote>\n<p>Andrew Witty, Chief Executive Officer, <abbr title=\"Glaxo SmithKline\">GSK<\/abbr>, said:<\/p>\n<blockquote>\n<p class=\"last-child\">Large parts of the <abbr title=\"United Kingdom\">UK<\/abbr>\u2019s life sciences base has strong links with Europe whether that be for trade, manufacturing, scientific research collaborations or the harmonised regulatory drug approval system. Leaving the <abbr title=\"European Union\">EU<\/abbr> would create uncertainty and potentially add complexity. That\u2019s why <abbr title=\"Glaxo SmithKline\">GSK<\/abbr> sees advantages in remaining in the <abbr title=\"European Union\">EU<\/abbr>.<\/p>\n<\/blockquote>\n<p>Steve Bates, Chief Executive Officer, BioIndustry Association said:<\/p>\n<blockquote>\n<p class=\"last-child\">We are concerned that the lack of clarity around what would happen to the regulation, patents ecosystem, financing and funding for <abbr title=\"United Kingdom\">UK<\/abbr> bioscience if the <abbr title=\"United Kingdom\">UK<\/abbr> were to leave the <abbr title=\"European Union\">EU<\/abbr> creates risk and uncertainty that could undermine the future success of the sector. It\u2019s vital the <abbr title=\"United Kingdom\">UK<\/abbr> remains engaged in the <abbr title=\"European Union\">EU<\/abbr> to influence legislative and regulatory policy developments affecting the life sciences ecosystem.<\/p>\n<\/blockquote>\n<p>Treasury analysis has already shown the average household would be \u00a34,300 a year worse off by 2030 were the <abbr title=\"United Kingdom\">UK<\/abbr> to leave a reformed Europe, and today\u2019s letter and statistics show how being out on our own would impact one of our strongest and most productive industries. In 2015 the <abbr title=\"United Kingdom\">UK<\/abbr>\u2019s life sciences sector &#8211; which spans pharmaceuticals, medical devices and digital health &#8211; saw around half of all pharmaceutical exports head to the <abbr title=\"European Union\">EU<\/abbr> \u2013 generating \u00a311 billion for the <abbr title=\"United Kingdom\">UK<\/abbr> economy last year.  <\/p>\n<p>The new data also showed life sciences in the <abbr title=\"United Kingdom\">UK<\/abbr> supports over 220,000 jobs in the sector and across the supply chain, with two-thirds of jobs outside of London and the South East, and many concentrated in the East of England and the North West. The growth in employment has been driven by <abbr title=\"United Kingdom\">UK<\/abbr>\u2019s leadership in emerging sectors like digital health \u2013 which has seen 23% growth per year since 2011 &#8211; and in advanced therapies manufacturing with over 35% average annual growth in turnover since 2011.<\/p>\n<p>The <abbr title=\"United Kingdom\">UK<\/abbr>\u2019s life sciences relationship with the European Union is clear \u2013 as one of the largest beneficiaries of European Union research funding, second only to Germany, British scientists are accessing investment to develop treatments for issues such as meningitis and flu. The <abbr title=\"United Kingdom\">UK<\/abbr> also benefits from <abbr title=\"European Union\">EU<\/abbr>-wide research programmes which are developing treatments for a range of diseases such as dementia, and the rare disease <abbr title=\"Metachromatic Leukodystrophy\">MLD<\/abbr>, which limits cognitive development amongst children.<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>The UK\u2019s leading life science companies warn that leaving the EU could bring uncertainty to the industry.<\/p>\n","protected":false},"author":8,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"_links":{"self":[{"href":"https:\/\/mostafa.openonline.co.uk\/index.php?rest_route=\/wp\/v2\/posts\/70286"}],"collection":[{"href":"https:\/\/mostafa.openonline.co.uk\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mostafa.openonline.co.uk\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mostafa.openonline.co.uk\/index.php?rest_route=\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/mostafa.openonline.co.uk\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=70286"}],"version-history":[{"count":0,"href":"https:\/\/mostafa.openonline.co.uk\/index.php?rest_route=\/wp\/v2\/posts\/70286\/revisions"}],"wp:attachment":[{"href":"https:\/\/mostafa.openonline.co.uk\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=70286"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mostafa.openonline.co.uk\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=70286"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mostafa.openonline.co.uk\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=70286"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}